Highlights

  • Beamtree Holdings (ASX:BMT) reported AUD 29.192 million in FY26 revenue.
  • Recurring Revenue reached AUD 27.548 million, representing 94% of total revenue.
  • An AUD 13.128 million Impairment contributed to an AUD 18.272 million net loss.
  • The company continued international healthcare software activity and prepared for its November AGM.

Beamtree Holdings Limited (ASX:BMT) develops healthcare software that converts clinical and administrative data into decision support, coding quality and performance insights for health systems. On 13 November 2026, its shares were priced at AUD 0.073, up 1.39% for the trading session. Its latest financial disclosures show higher Recurring Revenue alongside substantial non-cash impairments, while its 2026 activity has included international customer contracts and changes in executive leadership.

Healthcare Data Platforms and International Operations

Beamtree (ASX:BMT) provides software and analytical services for hospitals, health departments and other healthcare organisations. Its portfolio covers clinical coding, coding audit, health service benchmarking, decision-support automation and quality measurement. Offerings include PICQ for coding quality, RippleDown decision-support technology and solutions intended to help care providers identify variation in clinical activity and resource use.

The company reported that its products served more than 193 end customers across 25 countries during FY26. Its operating reach spans Australia, New Zealand and international markets, including activities involving health organisations in the United Kingdom, Ireland and the Middle East. Rather than selling medical treatments, Beamtree supplies information systems and services used in managing healthcare data and operational processes.

2026 Contracts, Management Changes and Product Direction

In May 2026, Beamtree announced an approximately AUD 2 million contract with Fakeeh Care Group in Saudi Arabia, alongside an interim update on its strategic review. Its other 2026 communications described activity in health analytics, coding quality and collaboration with healthcare organisations. These developments reflect a focus on recurring software and service relationships in selected international markets.

Gareth Pye was appointed Chief Executive Officer in June 2026 and commenced in the role in July. The company also disclosed the resignation of its chief financial officer in July. Its FY26 report described decisions to reassess particular software Assets and concentrate resources on products with clearer commercial relevance. Product changes included the discontinuation or impairment of certain legacy functionality, rather than uniform Investment across its full historical portfolio.

Beamtree (ASX:BMT) published its Annual Report and notice of Annual General Meeting in October 2026. The meeting was scheduled for 26 November, creating a forthcoming opportunity for shareholders to consider formal company Business and management commentary. The meeting notice itself does not establish any subsequent operating outcome.

FY26 Financial Results and Healthcare Technology Context

Revenue for the year ended 30 June 2026 was AUD 29.192 million. Recurring revenue amounted to AUD 27.548 million, or 94% of the total, while non-recurring revenue was AUD 1.644 million. Management reported recurring revenue growth of 10% and a decline of 54% in non-recurring revenue. The mix indicates greater concentration in subscriptions, licences and usage-related income, although individual contract renewals remain important.

Total operating expenses were AUD 28.830 million, including AUD 21.553 million in personnel expenses. Operating profit was AUD 362,000, and reported Earnings before interest, tax, Depreciation and Amortisation were AUD 310,000. The company nevertheless recorded an AUD 18.272 million statutory net loss, substantially affected by AUD 9.570 million in Goodwill impairment and AUD 3.558 million in software impairment.

At 30 June 2026, cash and cash equivalents totalled AUD 2.510 million. Net operating cash inflow for FY26 was AUD 931,000, while investing activities used AUD 3.893 million, mainly including intangible asset expenditure. Its accounts also recorded AUD 3.288 million in current borrowings. These figures distinguish accounting losses from cash generation but underline the importance of liquidity, Capital spending and financing arrangements.

Healthcare data vendors operate within procurement-intensive and regulated environments. Product adoption depends on integration with existing clinical information systems, data reliability, privacy controls and demonstrated use within hospital workflows. Beamtree’s recurring revenue model can support contract continuity, but delivery schedules and customer budgets influence the timing of additional revenue.

Risks and Operational Milestones

Key issues for Beamtree include converting contracts into recognised revenue, managing development expenditure and retaining clients as software products evolve. The FY26 impairments illustrate the accounting consequences when expected benefits from acquired or developed assets are revised. Liquidity, borrowings, management transitions and the concentration of resources on selected solutions also Warrant continued monitoring.

Upcoming information to watch includes the November 2026 annual general meeting, subsequent FY27 revenue and Cash Flow disclosures, performance of international contracts and updates on the company’s strategic priorities. Progress in coding automation and healthcare analytics will be measurable through reported customer activity, recurring revenue, margins and operating cash movements rather than announcements alone.

Key Insights

Beamtree (ASX:BMT) ended FY26 with a predominantly recurring revenue base and international exposure in healthcare data services. Its statutory loss reflected material impairments, while Operating Cash Flow remained positive for the year. Future financial reports will clarify how product prioritisation, customer contracts and available funding translate into the company’s ongoing operating profile.